CRISPR and Beta-Thalassemia (BT)

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Caribou Biosciences gets closer to Phase 3 with its gene-edited cell therapy candidate for large B-cell lymphoma, and Editas Medicine reports positive...

Located in the ETH Innovation & Entrepreneurship Lab in Zürich (Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies...

In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

In this roundup, we provide a summary of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...

This week's clinical update features news from Editas Medicine, which recently announced that the U.S. Food and Drug Administration (FDA) has granted...